Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb;16(1):79-87.
doi: 10.1007/s12975-024-01268-3. Epub 2024 Jul 2.

Radiomics-Based Predictive Nomogram for Assessing the Risk of Intracranial Aneurysms

Affiliations

Radiomics-Based Predictive Nomogram for Assessing the Risk of Intracranial Aneurysms

Sricharan S Veeturi et al. Transl Stroke Res. 2025 Feb.

Abstract

Aneurysm wall enhancement (AWE) has the potential to be used as an imaging biomarker for the risk stratification of intracranial aneurysms (IAs). Radiomics provides a refined approach to quantify and further characterize AWE's textural features. This study examines the performance of AWE quantification combined with clinical information in detecting symptomatic IAs. Ninety patients harboring 104 IAs (29 symptomatic and 75 asymptomatic) underwent high-resolution magnetic resonance imaging (HR-MRI). The assessment of AWE was performed using two different methods: 3D-AWE mapping and composite radiomics-based score (RadScore). The dataset was split into training and testing subsets. The testing set was used to build two different nomograms using each modality of AWE assessment combined with patients' clinical information and aneurysm morphological data. Finally, each nomogram was evaluated on an independent testing set. A total of 22 radiomic features were significantly different between symptomatic and asymptomatic IAs. The 3D-AWE mapping nomogram achieved an area under the curve (AUC) of 0.77 (63% accuracy, 78% sensitivity, and 58% specificity). The RadScore nomogram exhibited a better performance, achieving an AUC of 0.83 (77% accuracy, 89% sensitivity, and 73% specificity). The comprehensive analysis of IAs with the quantification of AWE data through radiomic analysis, patient clinical information, and morphological aneurysm metrics achieves a high accuracy in detecting symptomatic IA status.

Keywords: Aneurysm wall enhancement; Aneurysms; Radiomics.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethical Approval: Institutional Review Board number 202310190 was obtained for this retrospective analysis. Informed consent was not required for the study. Conflict of Interest: The authors declare no competing interests. Disclosures: SSV, AS, DJO, ES, SS, AG: None EIL: Board Membership: Stryker, NeXtGen Biologics, MedX Health, Cog-nition Medical, EndoStream; Consultancy: Claret Medical, GLG Con-sulting, Guidepoint, Imperative Care, Medtronic, Rebound Therapeu-tics, StimMed; Employment: University at Buffalo Neurosurgery Inc;Expert Testimony: renders medical/legal opinions as an expert witness;Stock/Stock Options: NeXtGen Biologics, Cognition Medical, RapidMedical, Claret Medical, Imperative Care, Rebound Therapeutics,StimMed AHS: inancial interest/investor/stock options/ownership: Adona Medical, Inc., Amnis Therapeutics, BlinkTBI, Inc.,Boston Scientific Corp. (for purchase of Claret Medical), BuffaloTechnology Partners, Inc., Cardinal Consultants, LLC, CerebrotechMedical Systems, Inc., Cognition Medical, Endostream Medical,Ltd, Imperative Care, Inc., International Medical Distribution Part-ners, Neurovascular Diagnostics, Inc., Q’Apel Medical, Inc., RadicalCatheter Technologies, Inc., Rebound Therapeutics Corp. (purchased2019 by Integra Lifesciences, Corp.), Rist Neurovascular, Inc., SenseDiagnostics, Inc., Serenity Medical, Inc., Silk Road Medical, Spin-naker Medical, Inc., StimMed, Synchron, Three Rivers Medical, Inc.,Vastrax, LLC, VICIS, Inc., Viseon, Inc.; consultant/advisory board:Amnis Therapeutics, Boston Scientific, Canon Medical Systems USA,Inc., Cerebrotech Medical Systems, Inc., Cerenovus, Corindus, Inc.,Endostream Medical, Ltd, Imperative Care, Inc., Integra LifeSciencesCorp., Medtronic, MicroVention, Minnetronix Neuro, Inc., North-west University—DSMB Chair for HEAT Trial, Penumbra, Q’ApelMedical, Inc., Rapid Medical, Rebound Therapeutics Corp., SerenityMedical, Inc., Silk Road Medical, StimMed, Stryker, Three RiversMedical, Inc., VasSol, W.L. Gore & Associates; national PI/steeringcommittees: Cerenovus LARGE trial and ARISE II trial, MedtronicSWIFT PRIME and SWIFT DIRECT trials, MicroVention FRED Trialand CONFIDENCE study, MUSC POSITIVE trial, Penumbra 3D Sep-arator trial, COMPASS trial, INVEST trial; research grants: co-inves-tigator, NIH/NINDS 1R01NS091075 Virtual Intervention of Intracra-nial Aneurysms; role: co-principal investigator, NIH-NINDS R21NS109575-01 Optimizing Approaches to Endovascular Therapy ofAcute Ischemic Stroke VMT: Financial interest/investor/stockoptions/ownership: Neurovascular Diagnostics, Inc., QAS.AI, Inc.;Consultant/advisory board: Canon Medical Systems USA; Researchgrants: Principal investigator, National Science Foundation Award No.1746694 and NIH NINDS award R43 NS115314-0; awardee of a Brain Aneurysm Foundation grant, a Center for Advanced Technology grant, and a Cummings Foundation grant EAS: Consultant for Medtronic, Microvention, Cerenovus, iSchemaView, and Rapid Medical

Figures

Figure 1:
Figure 1:. Analysis Pipeline.
Images were acquired with a 3T high resolution magnetic resonance imaging with and without contrast gadolinium. Segmentation of the aneurysm wall (shell) and aneurysm sac were performed in 3D Slicer. Radiomic analysis included extraction of enhancement (First order features), texture and shape features of the aneurysm wall. Transform-based RFs were not included in the figure, as these were not used for analysis. Significant RFs, clinical data and morphological aneurysm characteristics were used to build a machine learning model that accurately identified symptomatic aneurysms.
Figure 2:
Figure 2:. Overall workflow.
We split the dataset into training and testing datasets. The training dataset was used to evaluate six different machine learning models. We then evaluate the best machine learning model that can identify symptomatic IAs. The probability of this model was then used as an input to build two nomograms: Rad-Score and 3D mapping-based nomograms.
Figure 3:
Figure 3:. Final trained RadScore model.
(A) The bar plot shows odds ratios for all the radiomics features used in the RadScore model in descending order of importance. The radiomics feature are listed on the y-axis, while the odds ratios are shown on the x-axis, and also indicated at the end of each bar. (B) The overall AUC for the Rad-Score alone was 0.76, with an accuracy of 63% (67% sensitivity and 62% specificity). (C) The corresponding confusion matrix displaying the predicted asymptomatic and symptomatic cases alongside the true adjudications. RadScore had an accuracy of 63% (sensitivity 66.7% and specificity 62%).
Figure 4:
Figure 4:. Nomograms for RadScore (Composite Radiomics-based score) and 3D mapping models.
(A-B) Two nomograms were consutructed using RadScore, AWE metrics from 3D mapping, patient clinical information and aneurysm morphological metrics (gender= female 1 and male 0; location = 0 for low-risk location MCA or ICA, and = 1 for high-risk location Acom or posterior circulation; multiplicity = 0 for a single aneurysm in the patient and 1 for more than one aneurysm; hypertension = 0 for no hypertension and 1 for hypertension; and smoking =0 for never smoked and 1 for past or current smoker) and IA characteristics (size, SR, AR, irregularity = 0 for smooth regular shape and 1 for multi-lobulated irregular shape or has blebs). We observed that the RadScore-based nomogram had a higher accuracy, sensitivity and specificity compared to 3D mapping nomograms. (C) Confusion matrices of both the RadScore as well as the 3D mapping nomogram are shown. We observe that the RadScore model had a higher accuracy, sensitivity, specificity, and AUC as compared to the 3D mapping nomogram.

Update of

References

    1. Wiebers DO, Whisnant JP, Huston J 3rd, Meissner I, Brown RD Jr., Piepgras DG, Forbes GS, Thielen K, Nichols D, O’Fallon WM, et al. Unruptured intracranial aneurysms: natural history, clinical outcome, and risks of surgical and endovascular treatment. Lancet. 2003;362:103–110. doi: 10.1016/s0140-6736(03)13860-3 - DOI - PubMed
    1. Sanchez S, Hickerson M, Patel RR, Ghazaleh D, Tarchand R, Paranjape GS, Pope H, Ortega-Gutierrez S, Pederson JM, Hasan D, et al. Morphological Characteristics of Ruptured Brain Aneurysms: A Systematic Literature Review and Meta-Analysis. Stroke: Vascular and Interventional Neurology. 2023;3:e000707. doi: doi: 10.1161/SVIN.122.000707 - DOI
    1. Waqas M, Chin F, Rajabzadeh-Oghaz H, Gong AD, Rai HH, Mokin M, Vakharia K, Dossani RH, Meng H, Snyder KV, et al. Size of ruptured intracranial aneurysms: a systematic review and meta-analysis. Acta Neurochir (Wien). 2020;162:1353–1362. doi: 10.1007/s00701-020-04291-z - DOI - PubMed
    1. Bijlenga P, Gondar R, Schilling S, Morel S, Hirsch S, Cuony J, Corniola M-V, Perren F, Rüfenacht D, Schaller K. PHASES Score for the Management of Intracranial Aneurysm. Stroke. 2017;48:2105–2112. doi: doi: 10.1161/STROKEAHA.117.017391 - DOI - PubMed
    1. Backes D, Rinkel GJE, Greving JP, Velthuis BK, Murayama Y, Takao H, Ishibashi T, Igase M, terBrugge KG, Agid R, et al. ELAPSS score for prediction of risk of growth of unruptured intracranial aneurysms. Neurology. 2017;88:1600–1606. doi: 10.1212/wnl.0000000000003865 - DOI - PubMed

LinkOut - more resources